Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers

Detalles Bibliográficos
Autores principales: Zou, Limin, Qi, Yueli, Jiang, Yongling, Tang, Ling, Du, Yu, Zhao, Boyuan, Sun, Yanzhe, Xiang, Meiyi, Ma, Jun, Yang, Zhimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926957/
https://www.ncbi.nlm.nih.gov/pubmed/36683350
http://dx.doi.org/10.1002/cac2.12400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926957/
https://www.ncbi.nlm.nih.gov/pubmed/36683350
http://dx.doi.org/10.1002/cac2.12400

Ejemplares similares